

**INSTITUTIONAL BIOSAFETY COMMITTEE  
IBC MEETING MINUTES  
April 9, 2026**

**MEMBERS PRESENT:** JoEllyn McMillan - Chair, Pete Iwen – Vice Chair, Jim Kee, Jenna McKenzie, Jim Talmadge, Mimi McCann, Ryan Duden, Eric Bradley, Vinai Thomas, Noel Johnson, and Paul Denton

**NON-VOTING ALTERNATE MEMBERS PRESENT:** Mackenzie Conrin, Jared Evans, and Makayla Walker.

**ADMINISTRATIVE STAFF PRESENT:** Jackie Hollinger

**GUESTS PRESENT:** Stephen Asante-Adde

Dr. McMillan opened the meeting at 2:31pm.

**A. Review and Acceptance of IBC Minutes**

The IBC voted (11 in favor, 0 against, 0 abstention) to accept March 12, 2026 minutes.

**B. Information, Education and Policy Items**

none

**C. Special Notification/Review**

none

**D. Incident and Event Reports Special Notification and/or Review Approved**

- Centrifuge incident was discussed

**E. IBC Initial Research Proposals and/or Previously Tabled**

1) **IBC#:** 26-03-007-Pending

**PI:** Vyas, Yatin

**Title:** WASp modulates RPA function on single-stranded DNA in response to replication stress and DNA damage.

**Biohazardous Agents:** Human cell line/cells/tissues

**Applicable NIH Guidelines:** Exempt

**Summary:** Wiskott-Aldrich syndrome (WAS) is an inborn-error of immunity caused by deficiency of WASp. This protocol describes studies to investigate whether WASp plays an

essential role in normal DNA replication and the DNA stress-resolution pathway to identify sources of replication-stress-response associated genomic instability in WASp-deficient human lymphocytes. Human lymphocytes immortalized using Epstein-Barr virus (EBV) and human T-lymphotropic virus (HTLV) will be used.

**Committee Recommendation:** Approved, but a lab inspection is required.

**Training:** All training is completed and up to date.

**Motion:** Approved

**Vote Counts:** 11-0-0

## F. IBC Change in Protocol

### 2) IBC#: 25-01-001-ABL2

**PI:** Bothwell, Alfred

**Title:** Platelet-derived DKK1 and breast cancer metastasis

**Biohazardous Agents:** Murine cell line, lentiviral vector

**Applicable NIH Guidelines:** III-D-1-a, III-D-4-b

**Summary:** In this protocol, a lentiviral expression system will be used to express green fluorescence protein in a murine breast cancer cell line. The modified cells will be visualized in a transgenic mouse model that will be used to determine the role of platelet-derived DKK1 on tumor metastasis.

**Committee Recommendation:** Update to describe how 4T1 murine cells will be engineered to express luciferase. If using human cells for viral vectors, please add the information to Section II.2. Identify the source of all lentiviral vectors and murine cells that will be used in the laboratory. Change Section III.9 to ABL1, as ABL2 containment is not necessary for stably transfected 4T1 cells.

**Training:** All training is completed and up to date.

**Motion:** Conditionally Approved

**Vote Counts:** 11-0-0

## G. IBC Continuing Review Active Research

### 3) IBC#: 18-11-025-BL2

**PI:** D'Angelo, Christopher

**Title:** A Phase 2, Multi-Cohort, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with Clinical High-Risk Multiple Myeloma (KarMMA-2)

**Biohazardous Agents:** Human cell line/cells/tissues, Lentiviral vector

**Applicable NIH Guidelines:** III-C-1

**Summary:** This is a continuing review of a multi-cohort, open-label, multicenter Phase 2 study to evaluate the efficacy and safety of bb2121 in subjects with multiple myeloma (MM).

**Committee Recommendation:** Asked to address if the apheresis product is processed or stored on campus. Confirm that the individuals shipping the cells to the central laboratory are trained and following protocol. Asked if blood draws will be obtained at NMC. How and where will the blood be processed, stored, and shipped.

**Training:** One individual needs to complete training before final approval.

**Motion:** Conditionally Approved

**Vote Counts:** 11-0-0

- 4) **IBC#:** 10-07-012-ABL2  
**PI:** Dunaevsky-Hutt, Anna  
**Title:** Mechanisms of Development disorders.  
**Biohazardous Agents:** Adeno-associated virus, Human cell line/cells/tissues, Lentiviral vector  
**Applicable NIH Guidelines:** III-D-1-a, III-D-3-a, III-D-4-a  
**Summary:** This study uses viral vectors to express specific genes in brain cells to examine how neuronal and glial structure and function change in mouse models of neurodevelopmental disorders. Researchers will analyze these effects through brain slice experiments and live imaging. Additionally, human stem cell-derived astrocytes and neurons will be modified with fluorescent markers and introduced into mice to study their behavior and integration.  
**Committee Recommendation:** Ensure that all personnel handling AAB or LVV transfected cells on the associated IACUC protocols are listed as personnel on this IBC protocol.  
**Training:** Three individuals need to complete training before full approval.  
**Motion:** Approved.  
**Vote Counts:** 11-0-0
- 5) **IBC#:** 21-05-014-ABL2  
**PI:** Mathew, Grinu  
**Title:** Identifying regulators of metastasis in mouse models of prostate cancer  
**Biohazardous Agents:** CRISPR System Lentivirus-based, Human cell line/cells/tissues, Murine cell line, Murine primary cells, Lentiviral vector  
**Applicable NIH Guidelines:** III-D-1-a, III-D-3-a, III-D-4-a  
**Summary:** This study investigates prostate cancer progression from less aggressive forms to metastatic disease by identifying key transcription factors driving the transition. Mouse models and CRISPR gene-editing techniques are used. The study goal is to find molecular targets that could lead to more effective treatments.  
**Committee Recommendation:** In section I, assure that all personnel handling transfected cells on the associated IACUC protocols are listed on this IBC. In section II, if *E. coli*, is still in use, add it as an agent.  
**Training:** All training is complete and up to date.  
**Motion:** Conditionally Approved  
**Vote Counts:** 11-0-0
- 6) **IBC#:** 05-12-025-BL2  
**PI:** Solheim, Joyce  
**Title:** 1) Use of a murine retroviral vector in studies of antigen presentation; 2) Use of viral vectors in studies of antigen presentation and cancer biology  
**Biohazardous Agents:** Human cell line/cells/tissues, Retroviral vector  
**Applicable NIH Guidelines:** III-D-1-a, III-D-3-a  
**Summary:** This is a continuing review of a longstanding protocol with no changes. There are three related projects described. All projects relate to antigen presentation in major histocompatibility genes. Risks include MLV vectors to modify mouse genes involved in antigen presentation as well as the use of human cell lines.  
**Committee Recommendation:** Please update to provide the source of the viral vectors.  
**Training:** All training is complete and up to date.  
**Motion:** Conditionally Approved  
**Vote Counts:** 11-0-0

- 7) **IBC#:** Thomas, Vinai  
**PI:** 15-01-003-BL2  
**Title:** Bacterial adaptations during stress and infection.  
**Biohazardous Agents:** *Bacillus anthracis*, avirulent, *Enterococcus* species, *Staphylococcus aureus* (not vancomycin-resistant), *Staphylococcus aureus* vancomycin nonsusceptible, *Staphylococcus aureus*, methicillin-resistant, *Staphylococcus aureus*, methicillin-susceptible, *Staphylococcus* species not aureus.  
**Applicable NIH Guidelines:** Exempt  
**Summary:** This continuing review covers three different projects all using the same bacteria. The project characterizes the apoptosis like process during bacterial cell death and its relationship to biofilm formation. They seek to know the mechanism of bacterial cell death and address why the cell death is limited to a sub population of the bacterial culture.  
**Committee Recommendation:** Clarify what new mutants will be made and what the targets are. In this multi-project approach, please expand on how the bacteria will be used and tested. In Section II.5F, list the potential hosts.  
**Training:** All training is complete and up to date.  
**Motion:** Conditionally Approved  
**Vote Counts: 11-0-0**
- 8) **IBC#:** 17-07-016-ABL2  
**PI:** Iqbal, Javeed  
**Title:** Lentiviral and gamma retroviral expression vectors for cDNA and siRNA.  
**Biohazardous Agents:** Human cell line/cells/tissues, Murine primary cells, Lentiviral vector, Oncogene, Retroviral vector  
**Applicable NIH Guidelines:** III-D-1-a, III-D-3-a, III-D-4-a  
**Summary:** This study aims to understand how specific genes contribute to the development and progression of lymphoma. Viral vectors will be used to increase or decrease gene expression in various cell types, including normal and cancerous lymphocytes,  
**Committee Recommendation:** In Section II.2.C, please review the list of genes and update with any genes that may be missing. Identify which genes are oncogenes by adding "oncogene" next to the gene name. Briefly describe the gene function for each of the listed genes.  
**Training:** All training is complete and up to date.  
**Motion:** Conditionally Approved  
**Vote Counts: 11-0-0**
- 9) **IBC#:** 07-07-013-BL2  
**PI:** Zimmerman, Matthew  
**Title:** Role of oxygen species in angiotensin II-induced neuronal signaling  
**Biohazardous Agents:** Adenoviral vectors, Lentiviral vector  
**Applicable NIH Guidelines:** III-D-1-a, III-D-3-a  
**Summary:** This protocol describes studies to investigate the roles of reactive oxygen species as signaling molecules in the action of angiotensin II in development of neurogenic hypertension. The goal is to identify central targets of disease for development of therapeutic agents. No protocol or personnel changes.  
**Committee Recommendation:** No changes were recommended.  
**Training:** All training is complete and up to date.  
**Motion:** Approve  
**Vote Counts: 11-0-0**

There being no further business, Dr. McMillan adjourned the meeting at 3:08pm

Respectfully Submitted,



JoEllyn McMillan, PhD  
Chair, IBC  
JM

**ADDENDUM**  
**April 9, 2026**  
**IBC REVIEW LETTER/EMAIL TO INVESTIGATORS**

<b><u>IBC #</u></b>	<b><u>Date of Letter/Email</u></b>
26-03-007-Pending	4/10/2026
25-01-001-ABL2	4/10/2026
18-11-025-BL2	4/10/2026
10-07-012-ABL2	4/10/2026
21-05-014-ABL2	4/10/2026
05-12-025-BL2	4/10/2026
15-01-003-BL2	4/10/2026
17-07-016-ABL2	4/10/2026
07-07-013-BL2	4/10/2026